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The development of multidrug resistance (MDR) and subsequent relapse on therapy is a widespread problem in breast cancer,
but our understanding of the underlying molecular mechanisms is incomplete. Numerous studies have aimed to establish the role
of drug transporter pumps in MDR and to link their expression to response to chemotherapy. The ATP-binding cassette (ABC)
transporters are central to breast cancer MDR, and increases in ABC expression levels have been shown to correlate with decreases
in response to various chemotherapy drugs and a reduction in overall survival. But as there is a large degree of redundancy
between diﬀerent ABC transporters, this correlation has not been seen in all studies. This paper provides an introduction to the key
molecules associated with breast cancer MDR and summarises evidence of their potential roles reported from model systems and
clinical studies. We provide possible explanations for why despite several decades of research, the precise role of ABC transporters
in breast cancer MDR remains elusive.
1. Introduction
Resistance to chemotherapy is a major problem in the
management of breast cancer, where many of the initially
responsive tumours relapse and develop resistance to multi-
ple anticancer agents of diﬀerent structure and mechanism
of action [1]. This phenomenon is known as multidrug
resistance (MDR). The precise nature of chemotherapy resis-
tance, and the potential role of drug resistance genes involved
in the transport of anticancer agents, is still unclear. A better
understanding of the underlying molecular mechanisms of
chemotherapy resistance is required in order to develop
successful therapeutic strategies to overcome MDR.
Drug resistance can be mediated by a number of diﬀerent
mechanisms. It may be due to an increase in the activity of
ATP-dependent eﬄux pumps resulting in reduced intracel-
lular drug concentrations. Agents commonly associated with
this type of resistance include doxorubicin, daunorubicin,
vinblastine, vincristine and paclitaxel [2]. It can also be
caused by a reduction of cellular drug uptake. Water-soluble
drugs may attach to transporters carrying nutrients and
therefore fail to accumulate within the cell. Resistance to
drugs like cisplatin, 8-azaguanine and 5-fluorouracil is medi-
ated by this mechanism [3]. Another general mechanism
of resistance involves the activation of regulated detoxifying
systems such as the cytochrome P450 mixed function
oxidases, and also of increased DNA repair. In addition,
resistance can result from defective apoptotic pathways due
to malignant transformation [4], a change in the apoptotic
pathway during exposure to chemotherapy [5], or changes
in the cell cycle mechanisms that activate checkpoints and
prevent initiation of apoptosis. Other mechanisms involved
in drug resistance include lack of drug penetration, modifi-
cation of the ability to activate prodrugs and alterations in
drug targets. This paper will describe the main molecules
and mechanisms involved in MDR in breast cancer, and
summarise the results from key in vitro, in vivo and clinical
studies investigating their respective roles.
2. ABC Transporters
Several transmembrane transporter proteins have been
shown to be involved in the resistance of tumour cells
to chemotherapeutic agents. These proteins are termed
2 International Journal of Breast Cancer
Table 1: The ABC transporters expressed in breast tissue.
Gene Protein Tissue
Chemotherapeutic drugs
eﬄuxed by transporter
None chemotherapeutic
substrates
References
ABCB1 PGP/MDR1
Intestine, liver, kidney,
placenta, blood-brain
barrier, most tissues
Colchicine, doxorubicin,
etoposide, vinblastine,
paclitaxel
Neutral and cationic
organic compounds,
digoxin, saquinavir,
many commonly used
drugs
[2, 6–9]
ABCC1 MRP1 All tissues
Doxorubicin,
daunorubicin,
vincristine, etoposide,
colchicines,
camptothecins,
methotrexate
Glutathione and other
conjugates, organic
anions, leukotriene C4,
rhodamine
[2, 6–9]
ABCC4 MRP4
Prostate, testes, ovary,
intestine, pancreas, lung,
kidney, most tissues
6-mercaptopurine and
6-thioguanine and
metabolites,
methotrexate
Nucleotide analoges,
organic anions,
[6, 7, 10]
ABCC5 MRP5 Most tissues
6-mercaptopurine and
6-thioguanine and
metabolites
Nucleotide analogues,
cyclic nucleotides,
organic anions
[6, 7, 10]
ABCC10 MRP7
Low in all tissues except
pancreas
Nucleoside analogues [11]
ABCC11 MRP8
Low in all tissues except
kidney. Spleen, colon,
brain
5-fluorouracil [7, 8]
ABCC12 MRP9
Breast, testes, brain,
skeletal, ovary
Not known Not known [8, 12]
ABCG2 BCRP Liver, breast
Mitoxantrone,
topotecan, doxorubicin,
daunorubicin,
irinotecan, imatinib,
methotrexate
Prazosin, pheophorbide
A, Hoechst 33342,
rhodamine
[6, 13]
ATP-binding cassette transporters (ABC-transporters), and
utilise the energy of adenosine triphosphate (ATP) hydrolysis
to carry out biological processes. ABC transporters can be
divided into three functional categories: Importers mediate
the uptake of nutrients into the cell (amino acids, sugars, ions
and other hydrophilic molecules). Exporters/eﬄuxers pump
toxins and drugs out of the cell. The final category of ABC
proteins are involved in translation and DNA repair processes.
49 human ABC genes have been identified to date, these
have been divided into 7 subfamilies (ABCA-ABCG) based
on their sequence homology and domain organisation [14].
All proteins in the ABC family are characterised by two
distinct domains, the transmembrane domain TMD (also
known as the membrane spanning domain or the integral
membrane domain) and the nucleotide-binding domain
(NBD) (Figure 1). The TMD recognizes a variety of sub-
strates and undergoes conformational changes to transport
these across the membrane. The sequence and structure
of TMDs is variable, reflecting the chemical diversity of
substrates that can be translocated. The NBDor ATP-binding
cassette (ABC) domain is located in the cytoplasm and has
a fixed sequence and structure where ATP-binding occurs
[15]. Table 1 gives an overview of a number of diﬀerent ABC
transporters that have been linked to MDR in breast cancer.
We will focus on P-glycoprotein (PGP), multidrug resist-
ance-associated protein 1 (MRP1) and breast cancer resis-
tance protein (BCRP), themain ABC transporters implicated
in the development of multidrug resistance in breast cancer.
3. P-glycoprotein (PGP)
P-glycoprotein has a wide tissue distribution [16] and was
the first ABC transporter identified to be overexpressed in
breast cancer cell lines displaying MDR [17]. Mouse PGP,
which has 87% sequence morphology to human PGP in
a drug-binding state, has recently been described [18]. PGP
is a broad spectrum multidrug eﬄux pump that has 12
transmembrane domains and two ATP-binding sites [19]
(Figure 2). It is involved in the transport of neutral and
cationic hydrophobic compounds (vinblastine, vincristine,
doxorubicin, daunorubicin, etoposide and paclitaxel) out of
cells. For transport via PGP, extraction of the drug directly
from the cytoplasmic side of the lipid bilayer often occurs.
Most PGP substrates readily partition into the plasma
membrane and lipids are required for drug stimulated
ATPase activity. PGP is a unidirectional lipid flippase that
transports phospholipids from the inner to outer sections of
the bilayer [18].
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Figure 1: (a). An example of the general structure an ABC trans-
porter with 2 sets of transmembrane domains (TMD) and 2
nucleotide binding domains (NBD). Substrate molecules are
present in the inner membrane shown in orange. Upon binding of
ATP, the NBD become joined, leading to a conformational change
(b). This change causes the movement of the substrate out of the
membrane.
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Figure 2: Structure of P-glycoprotein (PGP)—this ABC transporter
consists of 12 transmembrane domains and 2 ATP binding sites.
Other transporters with a similar structure include MDR4, MRP4,
MRP5 and MRP7.
4. MDR-Associated Protein (MRP1)
MRP1 is also expressed in many diﬀerent organs and cell
types, including breast cancer cells [20]. Studies have demon-
strated that overexpression of MRP1 leads to cells becoming
resistant to a wide variety of anticancer drugs, for example,
doxorubicin [21]. MRP1 is a drug eﬄux transporter with
broad substrate specificity. For many drugs, MRP1-mediated
transport is stimulated by the presence of glutathione.
[22]. Unlike PGP, which tends to be located in the apical
membranes of epithelial cells, MRP1 is located basolaterally.
MRP1 has a similar structure to PGP, and also requires two
molecules of ATP as its energy source, but the nucleotide
binding sites 1 and 2 (NBD1 and NBD2) diﬀer in their
aﬃnity for ATP (Figure 3). The substrate binds to the MRP1
transmembrane domain causing a conformational change of
the protein, which initially induces ATP-binding at NBD1.
Further changes in conformation enhance ATP binding at
NBD2. When both NBD1 and NBD2 are occupied, the
bound substrate is transported out of the cell. ATP bound
at NBD2 is then hydrolysed, and the subsequent release of
ADP from NBD2 partially returns MRP1 back to its original
conformation, facilitating the release of the ATP bound at
NBD1 completing the cycle.
5. Breast Cancer Resistance Protein (BCRP)
BCRP is expressed in a variety of tumours and is associated
with resistance to a wide range of diﬀerent anticancer
agents including mitoxantrone, camptothecins, anthracy-
clines, flavopiridol and antifolates [23]. Unlike PGP and
MRP1, the BCRP protein contains only one transmembrane
domain and one nucleotide binding domain (Figure 4). Two
molecules of BCRP are bound by a disulfide bridge to form
a functioning homodimer [24]. The mechanism of drug
transport facilitated by BCRP has not been investigated in
as much detail as that of PGP and MRP1, but the basic
steps are thought to be similar, involving a cycle of substrate
transport and ATP hydrolysis [16]. Stem cells and tumour
cells in a hypoxic environment may be protected from
chemotherapeutic agents due to an increased expression of
BCRP induced by hypoxia [25]. However, this may not be
the case for all stem cells. Hoechst 33342 and rhodamine-
123 have been used to investigate the eﬄux eﬃciency of these
substrates in mammary stem cells [26]. Hoechst 33342 is
a substrate of BCRP and causes BCRP-positive cells to display
a unique “side population” phenotype [21, 27]. In the work
by Stingl et al., a small proportion of mammary stem cells
were found to possess a side population phenotype and only
a small minority of cells eﬄuxed Hoechst or rhodamine.
These data suggest that in contrast to haematopoietic stem
cells [26], there is no increase in BCRP in the mammary stem
cells.
6. Drug Resistance in Breast Cancer
Chemotherapy is central in the treatment of breast cancer,
but the development of drug resistance remains a problem.
Response rates to first line chemotherapies in metastatic
breast cancer, either single or a combination of drugs, are
around 30%–70%, and the disease-free period following
treatment is often only 7–10 months [28]. Table 2 gives an
overview of the main chemotherapy drugs used to treat
breast cancer and theirmechanism of action. The role of ABC
transporters in breast cancer MDR has been investigated by
evaluation of gene and protein expression in tumour samples
using RT-PCR, Western blot and immunohistochemistry.
The levels of expression have then been scored and linked
4 International Journal of Breast Cancer
N C
ATP ATP
Figure 3: Structure of Multidrug Resistance Protein 1 (MRP1)—
this ABC transporter is similar in structure to PGP in that they
possess 2 ATP binding sites. In addition to the 12 transmem-
brane domains, they also contain an additional 5 transmembrane
domains at the amino terminal end. Other transporters with
a similar structure include MRP2, MRP3 and MRP6.
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Figure 4: Structure of Breast Cancer Resistance Protein (BCRP)—
this ABC transporter contains 6 transmembrane domain and 1 ATP
binding site on the amino terminal side of the transmembrane
domain. This is known as a “half transporter,” these are thought
to form dimmers in order to function.
to treatment response and outcome. As will be discussed in
more detail in later sections, the data reported from these
studies have been conflicting, most likely caused by a number
of variable factors. For example, it is diﬃcult to generate
accurate overall measures of ABC transporter expression
due to the heterogeneity of the tumours and changes in
expression due to therapy. In addition, the large number of
diﬀerent proteins involved in mediating MDR means that
there is considerable redundancy in the system. Ultimately,
it is the combined activity of the expressed ABC transporters
over the course of disease progression that determines the
tumour response to therapy. This highly dynamic system
cannot be adequately captured simply by taking a snapshot
of the tumour.
7. Multidrug Resistance in Breast Cancer
Cells In Vitro
As studies in clinical material do not allow experimental
manipulation essential for dissecting the complex role of
ABC transporters in MDR, researchers have turned to in
vitro models. Expression levels of the relevant proteins have
been modified in breast cancer cell lines, and the resulting
changes in sensitivity to various chemotherapeutic agents
assessed. Eﬀects of anticancer drugs on expression levels of
the individual ABC transporters have also been determined,
alongside functional assays of ABC-mediated drug transport
across cell monolayers. Here we describe some examples of
in vitro approaches that have been utilised to investigate
the relationship between expression and activity of ABC
transporters and sensitivity to chemotherapy agents.
Hembruﬀ and colleagues generated a panel of MCF-7
cell lines selected for resistance to various chemotherapy
drugs, and used these to study how expression of drug
transporters related to drug uptake and sensitivity [29]. The
cell lines were resistant to either paclitaxel (MCF-7tax-2), doc-
etaxel (MCF-7txt), doxorubicin (MCF-7dox-2) or epirubicin
(MCF-7epi). Cellular uptake of 3H-paclitaxel, doxorubicin
and epirubicin was evaluated to determine any relationship
between drug accumulation and resistance. A threshold drug
concentration was required for both taxanes and anthra-
cyclins for the cells to acquire drug resistance, and there
was a significant degree of cross-resistance to drugs of
the same class. Taxane-resistant cells exposed for 2 weeks
to increasing concentrations of taxanes had significantly
reduced 3H-paclitaxel accumulation, with uptake as low as
2% of control in MCF-7tax-2 cells. Very similar data were
observed for anthracyclin-resistant cell lines, anthracyclin-
resistance was associated with a reduction in drug uptake.
However, in both cases there was no clear, dose-dependent
correlation between changes in drug accumulation and
degree of resistance. Whether the levels of expression of
MDR-associated transporters were linked to acquisition of
drug resistance was determined by real-time PCR analysis
and western blotting. There was a substantial increase in
ABCB1/PGP protein levels in MCF-7tax-2, MCF-7txt, and
MCF-7epi and in ABCC1/MRP1 in MCF-7dox-2 cells, sup-
porting that drug resistance is associated with both modified
drug accumulation and increased levels of a subset of ABC
transporter proteins. Taken together, the data in this study
suggest that whereas there is a link between the onset of drug
resistance and reduced drug uptake, additional mechanisms
must be involved in determining the sensitivity of the cells to
chemotherapy agents.
One method for determining the functional activity of
ABC transporters is by using the Caco-2 cell model of
transepithelial drug transport [30]. For the measurement
of apical to basolateral drug transport (i.e., absorptive), the
drugs are added to the apical side of the cell monolayer and
medium added to the basolateral side. At regular time inter-
vals medium is removed from the basolateral side and the
concentration of drug determined using high performance
liquid chromatography. The measurement of basolateral to
apical drug transport (i.e., secretory) is measured in the same
system by adding drugs to the opposite side of themonolayer.
When this model system was used to study transport of
belotecan and topotecan in the presence of PGP, MRP2 and
BCRP inhibitors, the inhibitors caused a significant reduc-
tion in the secretory flux of both drugs. Consistent with this
decrease, the absorptive fluxes of the drugs were significantly
increased by the apical presence of the inhibitors of PGP and
MRP1, but not by inhibitors of MRP2 or BCRP. These data
suggest that BCRP, PGP and MRP2 are all involved in the
transport of belotecan and topotecan, supporting that there
is considerable redundancy in theMDR system/components.
Other models for investigating transepithelial drug transport
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Table 2: Chemotherapy agents used to treat breast cancer subject to MDR.
Class of drug Drug Clinical use Mechanism of action
Anthracyclines Doxorubicin
Leukaemias, Hodgkin’s
Lymphoma, bladder,
breast, stomach, lung,
ovarian, thyroid, soft tissue
sarcomas, multiple
myeloma and more
Acts by intercalating DNA,
resulting in complex
formation which inhibits
DNA and RNA synthesis.
Triggers DNA cleavage by
topoisomerase II resulting
in cell death
Epirubicin
Breast, ovarian, gastric,
lung, and lymphomas
Acts by intercalating DNA
Taxanes Paclitaxel
Ovarian, breast, lung and
Kaposi’s sarcoma
Mitotic inhibitor; interferes
with the normal function
of microtubule breakdown.
Also induces apoptosis
Docetaxel Ovarian, breast and lung
Interferes with microtubule
breakdown
Vinca Alkaloids Vinblastine
Hodgkin’s Lymphoma,
lung, breast, head and neck
and testicular
It binds tubulin, thereby
inhibiting the assembly of
microtubules
Anti-metabolites 5-Fluorouracil
Breast, head and neck,
stomach, colon and some
skin cancers
Metabolised to cytotoxic
metabolites which are
incorporated into DNA and
RNA, inducing cell cycle
arrest and apoptosis
Methotrexate
Leukaemia, breast, skin,
head and neck and lung
Inhibits metabolism of folic
acid. Acts specifically
during DNA and RNA
synthesis, and thus it is
cytotoxic during the
S-phase of the cell cycle
Anthracenediones Mitoxantrone
Breast, Leukaemia,
Non-Hodgkin’s Lymphoma
and Prostate
Topoisomerase II inhibitor;
disrupts DNA synthesis and
DNA repair
include the use of MDCKII and LLC-PK cells overexpressing
one or several of the ABC transporters. A diﬀerence between
eﬄux ratios in the transfected cells compared to the parental
cells lines indicates transporter-mediated active drug uptake
or eﬄux.
The activity of ABC transporters (PGP, MRP1 and
BCRP) has also been investigated in MCF-7 wild-type and
BCRP overexpressing breast cancer cells [31]. The accumu-
lation of mitoxantrone and pheophorbide A was studied
in the presence of 50 μM tetrahydrocurcumin (a metabolite
of curcumin). Tetrahydrocurcumin inhibited the eﬄux of
mitoxantrone and pheophorbide A in the BCRP overexpress-
ing cells, but no eﬀect was observed in the wild type cells. The
group also assessed the activity of PGP by determining the
intracellular retention of [3H]-vinblastine in drug resistant
MCF-7MDR [32] and sensitive MCF-7 cells. Only in the drug
resistant cells did exposure to tetrahydrocurcumin result in
a significant dose-dependent increase of [3H]-vinblastine
accumulation when compared with a dimethyl sulfoxide
control. Tetrahydrocurcumin was seen to activate PGP-
mediated ATPase and to stimulate ATPase activity of BCRP.
[125I]-Iodoarylazidoprazosin ([125I]-IAAP), a photoactive
analogue of prazosin, was used in this study to characterise
the drug binding sites of PGP and BCRP. Tetrahydrocur-
cumin inhibited the incorporation of [125I]-IAAP into PGP
and BCRP in a dose-dependent manner, suggesting that this
drug binds directly to the substrate binding sites of PGP and
BCRP. Tetrahydrocurcumin was found to increase etoposide
sensitivity inMRP1 overexpressing cells and increase the sen-
sitivity of cells that overexpressed BCRP to mitoxantrone,
and sensitised drug resistant cells to vinblastine; suggesting
a reversal activity of tetrahydrocurcumin on the PGP-
mediated MDR phenotype.
Although ABC transporters are mainly localised in the
plasma membrane [33], they are also expressed in subcellular
compartments where they actively sequester drugs away from
their (cytoplasmic) targets [34]. It has been hypothesised
that BCRP could be expressed in the mitochondria and
thereby be involved in maintaining low concentrations of
anticancer drugs [35]. The functional activity of BCRP has
been investigated measuring the uptake of rhodamine 123
(rho 123) and mitoxanatrone in the presence or absence of
10 μmol/L of the BCRP inhibitor Fumitremorgin C [35].
This drug caused increased accumulation of mitoxantrone
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in parental (drug sensitive) cells but had no eﬀect on drug
uptake. Mitoxantrone accumulation in the cell lines that
overexpressed BCRP was significantly reduced following
exposure to Fumitremorgin C compared with the parental
cell lines, possibly due to BCRP-mediated eﬄux. To establish
whether BCRP is functionally active in the mitochondria,
eﬄux experiments were carried out in isolatedmitochondria.
Mitoxantrone eﬄux was elevated in mitochondria from the
BCRP overexpressing cells compared with levels seen in
mitochondria from the parental cells. These data suggest that
BCRP is functionally expressed in the mitochondria of MDR
cell lines and may be involved in protecting mitochondria
DNA from damage by chemotherapy drugs.
In 2007 a case study was published [36] exposing the
misidentification of the cancer cell line MCF-7AdrR (later
redesignated NCI/ADR-RES). These cells have been widely
used in research into multidrug resistance in breast cancer
during the last two decades. This study revealed that these
cells are derived from OVCAR-8 ovarian adenocarcinoma
cells and are not of breast origin as first thought. The
consequences of this misidentification leads to the need for
many studies to be reevaluated and relevant conclusions
made using OVCAR-8 cells as controls. In terms of breast
cancer research the studies would need to be repeated using
alternative cell lines.
8. Multidrug Resistance in In Vivo
Models of Breast Cancer
To gain further understanding of the complex system
involved in MDR, it is necessary to use in vivo models that
contain multiple cell types, and that include the tumour vas-
culature and immune cells. These models can also be used to
investigate the eﬀects of therapy on tumours in which MDR-
related genes have been either overexpressed or knocked out.
Two commonly used models are xenograft implantation of
human breast cancer cells in immunocompromised mice,
and a genetically engineered mouse model of hereditary
breast cancer. The following section will review data reported
from studies that have used in vivo models to investigate the
role of the ABC transporters on treatment response.
A genetically engineered mouse model of hereditary
breast cancer (K14cre; Brca1F/F ; p53F/F) has recently been
used to investigate drug resistance [37]. In this model,
the mammary tumours that spontaneously develop mimic
key features of human breast cancer-(BRCA1)-associated
mammary carcinomas. BRCA1 is essential for the repair of
double-strandedDNAbreaks by homologous recombination
and hence the Brca1−/−/p53−/− tumours tested were sen-
sitive to the DNA interacting drugs cisplatin, doxorubicin,
topotecan and carboplatin. The tumours could not be
eradicated and eventually acquired resistance to doxorubicin
and topotecan. A major characteristic of the doxorubicin
resistance was found to be increased expression of mdr1a
and mdr1b genes that encode the murine drug transporter
PGP. A 5-fold increase above the average mdr1a and mdr1b
transcription levels of untreated tumours was suﬃcient
to cause doxorubicin resistance [37]. Mdr1 gene expres-
sion levels were determined in doxorubicin-sensitive and
doxorubicin-resistant mouse mammary tumours in com-
parison with selected normal tissue from the large intestine
(mdr1a) or kidneys (mdr1b). The average level of mdr1
mRNA in untreated tumours was comparable with the
normal tissue. In 11 out of 13 resistant tumours at least
a 2-fold increase of mdr1 mRNA levels above the average
of untreated tumours was detected. Doxorubicin-resistant
tumours have been shown to largelymaintain their resistance
phenotype following subsequent orthotopic transplantation
into syngeneic animals [38].
The importance of PGP in doxorubicin-resistance
has been investigated using the PGP inhibitor tariq-
uidar in Brca1−/−;p53−/− mammary tumours generated in
K14cre;Brca1−/−;p53−/− mice [39]. Administration of tariq-
uidar (10mg/kg) before doxorubicin (5mg/kg) successfully
reversed doxorubicin resistance in three individual tumours
which had increased level of mdr1 mRNA. However, despite
the tumours becoming resensitised to doxorubicin they were
not eradicated by the treatment combination of doxorubicin
and tariquidar. The authors suggest this may be due to
dormancy of residual tumour-initiating cells, and that
inhibiting PGP is not enough to resensitise all tumour cells
to doxorubicin [37]. These results highlight an important
limitation of the potential use of PGP inhibitors in the
clinical setting.
PGP has also been shown to contribute to resistance of
novel targeted therapies such as the poly-(ADP-ribose) poly-
merase 1 (PARP 1) inhibitor AZD2281 [40]. In a genetically
engineered mouse model (GEMM) for BRCA1-associated
breast cancer, AZD2281 treatment inhibited tumour growth
without signs of toxicity. However, long-term treatment
resulted in the development of drug resistance which was
associated with an up-regulation of genes encoding for the
PGP eﬄux pump. This resistance to AZD2281 was reversed
by coadministration of the PGP inhibitor tariquidar, sup-
porting that the resistance was mediated through increased
PGP expression levels.
The (K14cre;Brca1−/−;p53−/−) mouse model has also
been used to demonstrate the involvement of BCRP in resis-
tance to topotecan. In this study, tumour bearing animals
were treated with topotecan, alone or in combination with
PARP inhibitor olaparib [41]. Although topotecan treatment
did prolong survival, all tumours eventually acquired resis-
tance. This may have been caused by overexpression of BCRP
and/or reduced levels of the drug target. Tumour-specific
ablation of Abcg2 (the gene coding for BCRP) significantly
reduced tumour growth and increased overall survival of
topotecan treated animals. Despite a lack of BCRP, none
of the BCRP−/−;BRCA1−/−;p53−/− tumours were completely
eradicated, even in the treatment group including olaparib.
However, it was noted that olaparib substantially increased
topotecan toxicity, and this may also occur in humans. The
study supports that BCRP expression is involved in the
development of resistance to topotecan.
As already mentioned, tumour heterogeneity combined
with biopsy inaccuracy contributes to variability and limit
histological and mRNA based detection of MDR pump
proteins [42]. Therefore it would be useful to be able to
quantify levels of pump protein expression throughout the
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whole tumour, rather than taking a local biopsy. Noninvasive
imaging of PGP-mediated transport has been developed,
using a range of radiolabelled drugs including daunoru-
bicin [43], and metal complexes such as 99mTc-MIBI [44].
Although this is a reproducible technique, the need for spe-
cialised equipment precludes routine use. Van Leeuwen and
colleagues have demonstrated the potential for functional
imaging techniques using the K14cre; Brca1F/F ; p53F/F mouse
model for hereditary mammary carcinoma [45]. Small pieces
of tumours expressing either basal, intermediate, or high
levels of mdr1a/b (the mouse equivalent of PGP) were
implanted in the mammary fat pad of wild type F1 animals.
99mTc-MIBI time intensity curves were generated for each
of the tumours during the first 30 minutes after injection.
Comparison of the tumours expressing basal and high levels
of PGP revealed that elevated PGP expression can be directly
correlated with an increase in the 99mTc-MIBI eﬄux rate.
Administration of the PGP inhibitor tariquidar (10mg/kg,
10 minutes before imaging the tumours) showed that in
the presence of the inhibitor the rate of 99mTc-MIBI eﬄux
did not depend on mdr1a/b expression levels. These data
support that 99mTc-MIBI imaging eﬀectively visualises the
eﬀect of PGP inhibitors on PGP-mediated transport. The
authors suggest that it is possible to classify tumours based
on their PGP transport activity, and also to directly link
treatment outcome to the measured PGP-mediated 99mTc-
MIBI eﬄux rates. Their model suggests a high probability of
drug resistance in the intermediate and high PGP expression
level tumours, demonstrating the potential for future clinical
use of functional imaging in predicting MDR.
9. Multidrug Resistance in
Breast Cancer—Clinical Studies
It is well established that many breast tumours that initially
respond to treatment subsequently develop resistance to
a broad range of drugs. Currently anthracycline-based
chemotherapy is a standard treatment for breast cancer, with
doxorubicin and its analogue epirubicin extensively used in
combination with 5-fluorouracil and cyclophosphamide. All
of these compounds are substrates for the ABC transporters
and are therefore subject to MDR. As a result, a number
of studies have aimed to relate the levels of MDR-pumps
in breast tumours to clinical outcome, and we give some
examples in the following sections.
Park and colleagues used gene expression profiling to
determine whether the expression pattern of a panel of ABC
transporters can be used to predict response to neoadjuvant
chemotherapy in breast cancer [46]. 21 patients received 4
courses of 5-fluorouracil, epirubicin and cyclophosphamide,
followed by a 12-week-course of paclitaxel, and were then
split into two groups; Those that had no pathological evi-
dence of any residual cancer cells and those with some resid-
ual tumour after completion of neoadjuvant chemotherapy.
The average tumour expression of each transcript on the
ABC transporters was determined using PCR. In tumour
samples taken before treatment started a number of ABC
transporters were expressed at over 50-fold higher levels
than the median values. This large variation in expression
levels between the individual tumours may have been due
to diﬀerences in disease stage, human epidermal growth
factor status, oestrogen receptor status and/or node status.
Following microarray analysis, several of ABC transporters
showed diﬀerential expression between the two groups of
patients. ABCC7, ABCF2 and ABCB2 were expressed at high
levels in the tumours of patients with no residual disease. In
contrast, ABCC5, ABCA12, ABCA1, ABCC13, ABCB6, and
ABCC11 were expressed at significantly higher levels in the
patients with residual disease and this was associated with
decreased in responsiveness to neoadjuvant therapy. ABCC5
has been reported to confer resistance to 5-fluorouracil [47]
and showed the highest gene expression level in tumours
with decreased response. The authors suggest that estab-
lishing the tumour ABC transporter gene expression profile
may be useful in predicting the pathological response to 5-
Fluorouracil, epirubicin and cyclophosphamide treatment in
breast cancer patients, but a larger cohort of patients needs
to be investigated to confirm whether this is the case.
The potential prognostic impact ofMDR gene expression
in breast cancer patients has also been investigated in the
adjuvant setting [48]. Expression of PGP and MRP1 was
measured in breast cancer tissue from 171 patients treated
by surgery, adjuvant chemotherapy +/− radiotherapy +/−
hormonal therapy. Using RT-PCR, 58% of the tumours (n =
68) expressed PGP and MRP1 was expressed in 92.4% out
of 131 tumours. This study did not reveal any statistically
significant correlation between PGP and MRP1 expression
and the 5-year disease-free survival or overall survival.
A number of studies have been designed to demonstrate
a link between expression of MDR proteins and response to
treatment/survival in breast cancer. In a study of 85 node-
positive breast cancer patients receiving anthracycline-based
adjuvant therapy, no significant influence of PGP or MRP1
expression was seen on progression-free or overall specific
survival [49]. This study was supported by data observed
by Kanzaki et al. [50]. Expression levels of PGP, MRP1
and BCRP were measured using RT-PCR in tumours from
38 breast cancer patients that received doxorubicin-based
chemotherapy after surgery. Expression levels of BCRP were
low in comparison with PGP and MRP1 and were not related
to relapse or prognosis.
In contrast, a link between PGP gene expression and
progression-free survival in advanced disease has been
reported in a study of 59 patients with primary operable
breast cancer [51]. Patients with no change in tumour size
for more than 6 months were defined as having prolonged
stable disease. Patients with progressive disease or stable
disease with progression within 6 months were classified
as nonresponders. The remaining patients were classified as
having either a complete or partial response. 22 patients
(37%) had a response to treatment, 12 patients (20%)
had prolonged stable disease and 25 patients (42%) did
not respond to the chemotherapy. The expression of a
number of ABC transporters was evaluated in tumour
samples from these patients and related to their response
to the diﬀerent chemotherapy regimes. The results can be
seen in Table 3 (adapted from [51]). Significant positive
correlations between the mRNA levels of drug resistance
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Table 3: Eﬀect of ABC transporters on patient response rate to chemotherapy.
All chemotherapy
Cyclophosphamide. Methotrexate and
5-Fluorouracil
5-Fluorouracil, epirubicin/doxorubicin
and cyclophospamide
All patients 34/59 (58%) 15/28 (54%) 19/31 (61%)
Low BCRP 27/42 (64%) 11/20 (55%) 16/22 (73%)
High BCRP 7/17 (41%) 4/8 (50%) 3/9 (33%)
Low MRP1 18/30 (60%) 8/16 (50%) 10/14 (71%)
High MRP1 16/29 (55%) 7/12 (58%) 9/17 (53%)
Low MRP2 18/28 (64%) 5/8 (63%) 13/20 (65%)
High MRP2 13/28 (46%) 8/18 (44%) 5/10 (50%)
Low PGP 32/47 (68%) 13/22 (59%) 19/25 (76%)
High PGP 2/12 (17%) 2/6 (33%) 0/6 (0%)
genes and treatment outcome were seen in particular for
PGP/BCRP and PGP/MRP1, in agreement with previous
reports [52].
Whether MRP1 expression correlates with patient and
tumour characteristics was studied in primary breast tumour
samples from 259 patients using immunohistochemistry
[56]. No significant diﬀerences in MRP1 levels were observed
according to patient age, menopausal status, tumour size,
nodal status or diﬀerentiation grade. Cox regression anal-
ysis was performed on subgroups of patients stratified by
menopausal status, tumour size, nodal status and adjuvant
systemic therapy. In node-negative patients with small
tumours, MRP1 expression were found to be associated
with decreased survival. In node positive patients who
received adjuvant systemic chemotherapy, expression of
MRP1 was associated with an increased risk of relapse. These
data suggest that MRP1 may play a role in chemotherapy
resistance in breast cancer, and to be a predictor of poor
prognosis in patients that receive first line systemic treatment
for recurrence [56]. Although the gene expression levels of
PGP in patient samples varied greatly (100-fold), it was still
a statistically significant predictor for the type of response to
chemotherapy and length of progression-free survival in the
cohort of advanced breast cancer patients.
Expression levels of MDR transporters are reported to
correlate with disease progression and response to treatment
in a study of 104 patients primary invasive breast cancer.
High expression levels of PGP as observed by immunohis-
tochemical staining was found to be associated with a higher
grade, lymph node involvement, shorter overall survival and
a shorter progression-free period [57]. This is supported by
a smaller study of 27 breast cancer patients that had all been
treated by adjuvant chemo-endocrine therapy after surgery
[54]. MRP1 expression was detected in 70% of the breast
cancer samples, and was significantly increased compared
with normal breast tissue. MRP1 expression levels were
higher in tumours of patients that subsequently relapsed
compared to those that did not. A study of 50 cases of locally
advanced breast cancer relating PGP expression and response
to neoadjuvant chemotherapy [53] suggests that PGP expres-
sion at diagnosis may predict a poor clinical response to
neoadjuvant chemotherapy. A significant correlation was
seen between high PGP expression prior to chemotherapy
and a poor clinical response. One important finding in this
study was that whereas 52% of the patient’s tumours were
PGP-positive prior to treatment, this increased to 73.5% after
treatment, illustrating the limitations of single-time point,
pretreatment studies.
MRP1 expression has been shown to correlate with
a shorter relapse-free survival and play a role in resistance
to chemotherapy in patients with early breast cancer treated
with cyclophosphamide,methotrexate and fluorouracil adju-
vant chemotherapy [55]. 1034 patients were stratified by
tumour size, number of involved lymph nodes, type of
surgery, tumour grade and hormone receptor status, and
randomly assigned to receive either six cycles of cyclophos-
phamide, methorexate and 5-fluorouracil or five years of
tamoxifen plus three years of goserelin.MRP1 expression was
evaluated using immunohistochemistry in tumour samples
obtained at the time of surgery and thus before adjuvant
therapy. Expression was categorised and the percentage of
patients in each category were similar negative (29% of
patients), low (17%), intermediate (25%) and high (29%).
There was a weak positive correlation between MRP1
expression and tumour size and grade. MRP1 expression
was not significantly correlated with age, lymph node status,
hormone receptor status or type of treatment. Univariate
analysis demonstrated that younger age, larger tumour size,
and a higher number of positive nodes, and increasing
levels of MRP1 expression were significantly associated with
a shorter relapse-free survival. Large tumour size, higher
number of involved lymph nodes, higher tumour grade and
higher MRP1 expression were also significantly associated
with a shorter overall survival. The independent eﬀects of
MRP1 expression on survival were assessed by multiple Cox
proportion hazards regression models, taking into account
diﬀerences in treatment regimes. In the patients treated
with cyclophosphamide, methotrexate and 5-fluorouracil,
higher MRP1 expression was associated with a shorter
recurrence-free survival and overall survival. In contrast,
in patients treated with tamoxifen and goserelin, MRP1
expression did not predict recurrence-free survival or overall
survival. This patient study indicates that MRP1 expression
independently predicts a shorter survival in patients treated
International Journal of Breast Cancer 9
Table 4: Overview of clinical studies investigating the eﬀect of ABC transporters.
Type of Study No. of patients Treatment Detection Method Outcome Author
Neoadjuvant 21 patients
5-fluorouracil, epirubicin,
cyclophosphamide and
paclitaxel
RT-PCR
Diﬀerences seen in expression
before treatment, no diﬀerence
in expression response to
treatment
[46]
Neoadjuvant 50
Cyclophosphamide,
doxorubicin and
5-fluorouracil
Immunohistochemistry
Significant correlation between
PGP expression prior to
treatment and clinical response
[53]
Adjuvant 171
Chemotherapy +/−
radiotherapy +/−
hormonal therapy
RT-PCR
No significant correlation
between PGP and MRP1
expression and survival
[48]
Adjuvant 85 Anthracycline based RT-PCR
No significant influence of PGP
or MRP1 expression on survival
[49]
Adjuvant 38 Doxorubicin RT-PCR
No correlation between MRP1
expression and survival
[50]
Adjuvant 27 Chemoendocrine RT-PCR
High expression levels of MRP1
increased risk of relapse. No
significant diﬀerence in PGP
expression
[54]
Adjuvant 1034
Cyclophosphamide,
methotrexate and
5-fluorouracil or
tamoxifen and goserelin
Immunohistochemistry
MRP1 expression predicts a
shorter survival in patients
treated with conventional
chemotherapy
[55]
Adjuvant 59
Cyclophosphamide,
methotrexate and
5-fluorouracil or
5-fluorouracil,
doxorubicin/epirubicin
and cyclophosphamide
RT-PCR
High PGP expression significant
predictor of poor prognosis
[51]
Adjuvant 259
Cyclophosphamide,
methotrexate and
5-fluorouracil
Immunohistochemistry
Increased expression of MRP1
associated with increase in
relapse and number of deaths
[56]
Adjuvant 104
Radiotherapy +/−
chemotherapy +/−
hormonal therapy
Immunohistochemistry
High expression levels of PGP
associated with shorter survival
[57]
with conventional chemotherapy and suggests treatment
failure in those patients.
The contradictory findings reported in a number of
clinical studies, may primarily be due to diﬀerences in
techniques used to assess the levels of MDR pumps. The
size and quality of the tumour sample available for study, as
well as its composition, is another source of variability. For
example, MRP1 mRNA has been detected in 98% of breast
cancer samples (containing mixed cell populations) whereas
MRP1 protein was detectable in only 53% of the samples
[55]. This illustrates that measurements of gene expression
alone is likely to lead to an overestimate of the presence
of MDR proteins. Alongside the diﬃculties in detecting the
transporters in tumours, intra- and inter-tumour hetero-
geneity makes reproducible measurements diﬃcult. Often
the diﬀerent proteins are expressed at very low levels, pre-
cluding accurate quantification by immunohistochemistry
or semi-quantitative RT-PCR [42, 58]. Studies of individual
MDR proteins may not be clinically meaningful, as tumours
express a whole range of proteins with overlapping func-
tions. Measurements of expression levels of the individual
proteins during a course of treatment would increase our
understanding of the interactions between the diﬀerent
transporters. Alongside this, information about how therapy
aﬀects the functional activity of diﬀerent ABC transporters
would elucidate the role they play in MDR.
Table 4 summarises the findings from key clinical stud-
ies investigating the expression of ABC transporters, and
illustrates the conflicting results reported regarding the
correlation of PGP and MRP1 response to therapy. In
general, studies using immunohistochemical methods to
detect protein conclude that high tumour levels of PGP and
MRP1 indicate shorter survival rates, and an increased risk
of relapse. These data suggest that assessing ABC transporter
expression levels in breast tumours may help predict patient
response to chemotherapy.
10. Conclusions
The exact role of ABC transporters in breast cancer MDR has
been diﬃcult to pinpoint due to the complexity of the mech-
anisms involved. Investigations into the expression of these
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proteins in breast cancer cells and tumour samples have often
proved inconclusive, and diﬀerences in the experimental
techniques have made it diﬃcult to directly compare results
between studies. Although a number of clinical studies have
reported that high levels of tumour ABC transporters are
associated with tumour progression, a clear link between
expression levels and tumour sensitivity to chemotherapy or
patient outcome has not been identified. Due to high number
of ABC transporters and the redundancy in their function,
charting the combined expression levels and functionality
may be required to reveal how they interact to generateMDR.
Overall, further comprehensive studies are needed to fully
elucidate the role that ABC transporters play in breast cancer
multidrug resistance. A better understanding of this complex
and dynamic system is essential to enable us to develop
therapeutic strategies that bypass MDR, and also eﬀective
ways of inhibiting MDR components to increase the eﬃcacy
of our current extensively used chemotherapies.
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